Abstract: An ultrasonic sensing system includes a comparator, an analog-to-digital converter (ADC) coupled to the comparator, and a processor coupled to the comparator and the ADC. The comparator is configured to compare an input signal with a triggering value and trigger proximity measurement in response to an amplitude of the input signal being greater than the triggering value. The ADC is configured to convert the input signal to a digital signal. The processor is configured to, in response to the proximity measurement being triggered, determine a peak time point when a peak amplitude is received based on the digital signal and calculate a distance based on the peak time point. The peak time point is different from a time point when the proximity measurement is triggered.

Abstract: A method and a device for measuring flight parameters of an unmanned aerial vehicle (UAV) are provided, the method includes, capturing images and collecting an angular velocity of the UAC, extracting corner points from a current frame image, estimating an estimated area according to the angular velocity of the UAV, searching for a corresponding corner point in the estimated area, obtaining a speed of each of the corner points, obtaining a pixel velocity, and obtaining an actual speed of the UAV based on the pixel velocity and a flight altitude of the UAV.

Abstract: Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I). or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q1, Q2, Z, R, R1, R2, R3, R4 and R5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

Abstract: An ultrasonic sensing system includes an ultrasonic receiver configured to receive an ultrasonic signal and a gain-adjustable amplifier operably coupled to the ultrasonic receiver. The gain-adjustable amplifier is configured to amplify the ultrasonic signal according to a variable gain determined based at least in part on a value of a timer that corresponds to a measuring distance.

Abstract: A convenient lid includes a housing, a lid opening, a press plate, a button, an insertion plate, a guide plate and a threaded body, the lid opening and the threaded body are provided on the lower part of the housing, the side of the lid is provided with a first concave cavity, a fixing body and a guide column are provided in the first concave cavity, a switch device and a security device are provided on the fixing body and the guide column, a guide plate, an insertion plate and a press plate are provided inside the lid, a concave ring and a guide strip are provided on the outside of the lid opening, a convex ring, a guide slot and a latch are provided on the inner side of the threaded body, ribs and threads are provided on the outer side of the threaded body.

Abstract: A method and a device for measuring flight parameters of an unmanned aerial vehicle (UAV) are provided, the method includes, capturing images and collecting an angular velocity of the UAC, extracting corner points from a current frame image, estimating an estimated area according to the angular velocity of the UAV, searching for a corresponding corner point in the estimated area, obtaining a speed of each of the corner points, obtaining a pixel velocity, and obtaining an actual speed of the UAV based on the pixel velocity and a flight altitude of the UAV.

Abstract: A method and a device for measuring flight parameters of an unmanned aerial vehicle (UAV) are provided, the method includes, capturing images and collecting an angular velocity of the UAC, extracting corner points from a current frame image, estimating an estimated area according to the angular velocity of the UAV, searching for a corresponding corner point in the estimated area, obtaining a speed of each of the corner points, obtaining a pixel velocity, and obtaining an actual speed of the UAV based on the pixel velocity and a flight altitude of the UAV.

Abstract: The disclosure relates to a convenient lid comprising a housing, a lid opening, a press plate, a button, an insertion plate, a guide plate and a threaded body, the lid opening and the threaded body being provided on the lower part of the housing, the side of the lid being provided with a concave cavity, a fixing body and a guide column being provided in the concave cavity, a switch device and a security device being provided on the fixing body and the guide column, a guide plate, an insertion plate and a press plate being provided inside the lid, a concave ring and a guide strip being provided on the outside of the lid opening, a convex ring, a guide slot and a latch being provided on the inner side of the threaded body, ribs and threads being provided on the outer side of the threaded body.

Abstract: Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

Abstract: Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

Abstract: An ultrasonic sensing system includes an ultrasonic receiver configured to receive an ultrasonic signal and a gain-adjustable amplifier operably coupled to the ultrasonic receiver. The gain-adjustable amplifier is configured to amplify the ultrasonic signal according to a variable gain determined based at least in part on a value of a timer that corresponds to a measuring distance.

Abstract: Methods, systems and device are provided for improving the range and accuracy of proximity measurement such as in ultrasonic sensing systems. In particular, the blind zone caused by reverberation signals can be reduced or eliminated by attenuating signals received during the time period corresponding to the blind zone without. In an implementation, an attenuator circuit is selected by a switch to process received signals during the blind zone time period and deselected by the switch after the time zone time period. Additionally, the accuracy and range of the measurement can be improved by varying the gain provided to the received signals based on the varying measuring distance. In an implementation, a gain-adjustable amplifier is controlled by a gain control signal to provide incremental gain as time increases.

Abstract: Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

Abstract: Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36), GLP-1(9-36), and oxyntomodulin, or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, R1, R2, R3, R4, R5, n, p and q are as defined herein.

Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

Abstract: Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

Abstract: Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

Abstract: Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36), GLP-1(9-36), and oxyntomodulin, or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, R1, R2, R3, R4, R5, n, p and q are as defined herein.

Abstract: Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP(1-42), PTH(1-34), Glucagon(1-29), GLP-2(1-33), GLP-1(7-36), GLP-1(9-36), oxyntomodulin and exendin variants.